Skip to content

Guided Therapeutics, Inc.: cash and cash equivalents

Guided Therapeutics cash and cash equivalents: $2.31 million at 2022-12-31, up 259.7% on the year. 14 values since 2009, each linked to its SEC filing.

All Guided Therapeutics, Inc. financial histories

At a glance

Guided Therapeutics reported cash and cash equivalents of $2.31 million at 2022-12-31, up 259.7% from $643.0 thousand a year earlier. Across the last five reported years it ranged from $0 (2018-12-31) to $2.31 million (2022-12-31). That was 68.7% of total assets ($3.37 million) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-12-31 to 2022-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Cash and cash equivalents in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2022-12-312,313,000USD2023-03-3010-K · 0001477932-23-001899 SEC
-2021-12-31643,000USD2023-03-3010-K · 0001477932-23-001899 SEC
-2020-12-31182,000USD2022-03-3010-K · 0001477932-22-001704 SEC
-2019-12-31899,000USD2021-04-0710-K · 0001654954-21-003915 SEC
-2018-12-310USD2020-04-2010-K · 0001654954-20-004236 SEC
-2017-12-311,000USD2020-04-2010-K · 0001654954-20-004236 SEC
-2016-12-3114,000USD2019-05-0810-K · 0001654954-19-005469 SEC
-2015-12-3135,000USD2018-04-2010-K/A · 0001654954-18-004170 SEC
-2014-12-31162,000USD2017-03-2210-K · 0001654954-17-002258 SEC
-2013-12-31613,000USD2016-03-1510-K · 0001121781-16-000420 SEC
-2012-12-311,045,000USD2015-03-2510-K · 0001121781-15-000054 SEC
-2011-12-312,200,000USD2014-03-2610-K · 0001121781-14-000055 SEC
-2010-12-313,268,000USD2013-03-2710-K · 0001121781-13-000037 SEC
-2009-12-31230,000USD2012-03-2810-K · 0001121781-12-000081 SEC

Related GUIDED THERAPEUTICS, INC. histories

All 52 Guided Therapeutics histories

Inspect the source

Entity
GUIDED THERAPEUTICS, INC. / CIK 0000924515
Captured
SEC response SHA-256
07253c51dd96bdfeda0ca7c761b14027da22cefe8a10fcb03d580eb664849f5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000924515.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))